BioStock Investor Pitch: Oncoinvent

Oncoinvent’s CEO Anders Månsson visited BioStock’s studio to talk about the development of the radiopharmaceutical Radspherin for peritoneal carcinomatosis. In his presentation, he delves into the results from the phase I/IIa studies with Radspherin and the upcoming clinical development plan. Furthermore, he talks about Oncoinvent as an investment opportunity and the unmet medical need for these cancer patients. 

Watch Anders Månsson present Oncoinvent at biostock.se:

https://www.biostock.se/en/2024/01/biostock-investor-pitch-oncoinvent/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se